No abstract available.
Psychopharmacology*

No abstract available.
Psychopharmacology*

No abstract available.
Neurosciences* ; Psychopharmacology*

No abstract available.
Adolescent* ; Child* ; Humans ; Psychopharmacology*

Improvement of psychopharmacology resulted in changes in therapeutic target for patients with schizophrenia. Although the control of psychotic symptoms are considered to be the primary goal of treatment in schizophrenia, in recent years, functional recovery and improvement of quality of life (QoL) has been highlighted as the new therapeutic target. In this article, we reviewed the definition, assessment tools, and recent studies which have been done in Korea. QoL is complex and heterogenous concept, thus there have been no gold-standard measures for QoL. Standardization of assessment tools for Koreans has set the infrastructure for QoL researches in patients with schizophrenia. More researches are needed in this area, and it could provide information for the development of psychosocial program and systemic support for improving schizophrenic patient's QoL.
Humans ; Korea ; Psychopharmacology ; Quality of Life* ; Schizophrenia*

Recently, the Korean College of Neuropsychopharmacolgy (KCNP) published an English language journal "Clinical Psychopharmacology and Neuroscience" for the purpose of international communications in the area of neuropsychopharmacology and related biological psychiatry. Historically, it is the first foreign language journal published in the Korean psychiatric society. This is writing to the background of publishing an English language journal in the perspectives of the limitations of Korean language journal and the international communications with researchers all over the world. The major concerns in publishing an English language journal are discussed. The future plan of continuously publishing "Clinical Psychopharmacology and Neuroscience" and some suggestions for the researchers who are going to submit manuscripts and to read this journal are described. We hope this is helpful for the publication of English language journal planning in the editorial committee of the Korean Neuropsychiatric Association.
Biological Psychiatry ; Hope ; Psychopharmacology* ; Publications* ; Writing

In this review, we compared recommendations from the Korean Medication Algorithm Project for Depressive Disorder 2017 (KMAP-DD 2017) to other global treatment guidelines for depression. Six global treatment guidelines were reviewed; among the six, 4 were evidence-based guidelines, 1 was an expert consensus-based guideline, and 1 was an amalgamation of both evidence and expert consensus-based recommendations. The recommendations in the KMAP-DD 2017 were generally similar to those in other global treatment guidelines, although there were some differences between the guidelines. The KMAP-DD 2017 appeared to reflect current changes in the psychopharmacology of depression quite well, like other recently published evidence-based guidelines. As an expert consensus-based guideline, the KMAP-DD 2017 had some limitations. However, considering there are situations in which clinical evidence cannot be drawn from planned clinical trials, the KMAP-DD 2017 may be helpful for Korean psychiatrists making decisions in the clinical settings by complementing previously published evidence-based guidelines.
Complement System Proteins ; Depression ; Depressive Disorder* ; Psychiatry ; Psychopharmacology

The rapid development of psychotropic drugs and great advancement in psychopharmacology during the past recent years has altered the strategy of pharmacotherapy for major psychiatric disorders, and in turn, an active development of various clinical practice guidelines or algorithm has taken place. However, there could be problems with applying the foreign guidelines directly to our clinical situation, due to the differences in racial characteristics, socioeconomic conditions, government policy, and clinical practices. In addition, the changes of circumstances outside of clinical situation in Korea may distort clinical practices and may go even against the trend of recent psychopharmacology. As a solution to such problems, Korean Medication Algorithm Project for Major Psychiatric Disorders (KMAP) was launched with the support from the Korean Society of Psychopharmacology and Korean Academy of Schizophrenia. However, since clinical practice guidelines and algorithms contain not only the advantages, but also disadvantages and risks, sufficient consideration must precede the development of algorithms. Hence, this review provides a discussion on the definition of clinical guideline and its limitation, its advantages and disadvantages, and the need for the development of clinical guideline in psychiatric field. Also, developing source, dissemination and implementation of clinical practice guidelines were also discussed. We hope that this review can make the purpose of KMAP clear and elicit the productive criticism on Korean algorithm.
Drug Therapy ; Hope ; Korea ; Psychopharmacology ; Psychotropic Drugs ; Schizophrenia

Development of new drugs using the incrementally modified drug (IMD) technique is becoming increasingly popular in the pharmaceutical industry. The technique addresses the critical need of pharmaceutical companies to reduce the astronomical budget required to develop a new drug. Incremental drug modification can encompass modification of the structure, formulation, or indication of existing drugs. Typical examples of the technique include modification of chemical structure, changes to formulation, and development of compound drugs. While some large pharmaceutical companies use the technique as a strategic tactic to prolong patent rights and maintain a profitable brand, it can also offer many health benefits, such as the discovery of new uses for the same compound, improved safety, and raised patient compliance. Several incrementally modified drugs have already been marketed for psychiatric use, and many more are waiting for approval. This new trend may expand the options available to clinicians; the usefulness of chiral and long-acting drugs has already been proven in clinical practice. This review presents an overview of the incrementally modified drug technique and its current status in psychopharmacology. It also discusses the economic and clinical implications of the current popularity of this technique.
Budgets ; Drug Industry ; Human Rights ; Insurance Benefits ; Patient Compliance ; Psychopharmacology*

Development of new drugs using the incrementally modified drug (IMD) technique is becoming increasingly popular in the pharmaceutical industry. The technique addresses the critical need of pharmaceutical companies to reduce the astronomical budget required to develop a new drug. Incremental drug modification can encompass modification of the structure, formulation, or indication of existing drugs. Typical examples of the technique include modification of chemical structure, changes to formulation, and development of compound drugs. While some large pharmaceutical companies use the technique as a strategic tactic to prolong patent rights and maintain a profitable brand, it can also offer many health benefits, such as the discovery of new uses for the same compound, improved safety, and raised patient compliance. Several incrementally modified drugs have already been marketed for psychiatric use, and many more are waiting for approval. This new trend may expand the options available to clinicians; the usefulness of chiral and long-acting drugs has already been proven in clinical practice. This review presents an overview of the incrementally modified drug technique and its current status in psychopharmacology. It also discusses the economic and clinical implications of the current popularity of this technique.
Budgets ; Drug Industry ; Human Rights ; Insurance Benefits ; Patient Compliance ; Psychopharmacology*